NASDAQ:AKRX - Akorn Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.22 -0.16 (-1.20 %) (As of 09/20/2018 04:00 PM ET)Previous Close$13.38Today's Range$13.12 - $13.4152-Week Range$10.76 - $33.63Volume1.30 million shsAverage Volume2.46 million shsMarket Capitalization$1.68 billionP/E Ratio8.31Dividend YieldN/ABeta1.92 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois. Receive AKRX News and Ratings via Email Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:AKRX CUSIP00972810 Webwww.akorn.com Phone847-279-6100 Debt Debt-to-Equity Ratio1.13 Current Ratio3.94 Quick Ratio2.87 Price-To-Earnings Trailing P/E Ratio8.31 Forward P/E Ratio35.73 P/E Growth1.59 Sales & Book Value Annual Sales$841.04 million Price / Sales1.97 Cash Flow$0.5201 per share Price / Cash25.42 Book Value$6.65 per share Price / Book1.99 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-24,550,000.00 Net Margins-24.21% Return on Equity-12.84% Return on Assets-5.48% Miscellaneous Employees2,308 Outstanding Shares125,450,000Market Cap$1.68 billion Akorn (NASDAQ:AKRX) Frequently Asked Questions What is Akorn's stock symbol? Akorn trades on the NASDAQ under the ticker symbol "AKRX." How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings data on Wednesday, August, 1st. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.14. The business had revenue of $190.94 million for the quarter, compared to the consensus estimate of $187.40 million. Akorn had a negative net margin of 24.21% and a negative return on equity of 12.84%. View Akorn's Earnings History. What price target have analysts set for AKRX? 6 brokerages have issued 1 year price targets for Akorn's stock. Their predictions range from $14.00 to $34.00. On average, they expect Akorn's stock price to reach $28.60 in the next year. This suggests a possible upside of 115.7% from the stock's current price. View Analyst Price Targets for Akorn. What is the consensus analysts' recommendation for Akorn? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn. Who are some of Akorn's key competitors? Some companies that are related to Akorn include Catalent (CTLT), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Endo International (ENDP) and Intercept Pharmaceuticals (ICPT). Who are Akorn's key executives? Akorn's management team includes the folowing people: Mr. Rajat Rai, Chief Exec. Officer (Age 51)Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55) Has Akorn been receiving favorable news coverage? Media headlines about AKRX stock have been trending somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Akorn earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Akorn. Who are Akorn's major shareholders? Akorn's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.55%), Gardner Lewis Asset Management L P (3.00%), Marshall Wace LLP (1.65%), Paulson & CO. Inc. (1.40%), Natixis (1.20%) and Northern Trust Corp (1.12%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky and John N Kapoor. View Institutional Ownership Trends for Akorn. Which institutional investors are selling Akorn stock? AKRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Schroder Investment Management Group, Renaissance Technologies LLC, Nexthera Capital LP, Gardner Lewis Asset Management L P, Wolverine Asset Management LLC, State Board of Administration of Florida Retirement System and California Public Employees Retirement System. Company insiders that have sold Akorn company stock in the last year include Brian Tambi and John N Kapoor. View Insider Buying and Selling for Akorn. Which institutional investors are buying Akorn stock? AKRX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Paulson & CO. Inc., Marshall Wace LLP, PointState Capital LP, Arrowgrass Capital Partners US LP, BlueMountain Capital Management LLC, BNP Paribas Arbitrage SA and Northern Trust Corp. View Insider Buying and Selling for Akorn. How do I buy shares of Akorn? Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Akorn's stock price today? One share of AKRX stock can currently be purchased for approximately $13.26. How big of a company is Akorn? Akorn has a market capitalization of $1.68 billion and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe. How can I contact Akorn? Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected] MarketBeat Community Rating for Akorn (NASDAQ AKRX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 449 (Vote Outperform)Underperform Votes: 361 (Vote Underperform)Total Votes: 810MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: How Do Tariffs Affect Trade Balances?